Pharmaceutical - Asia-Pacific, Novartis

Filter

Current filters:

Asia-PacificNovartis

Popular Filters

1 to 25 of 32 results

Novartis gets fourth indication, DME, for Lucentis in Japan

24-02-2014

Swiss drug major Novartis says it has received approval from Japanese regulatory bodies for a fourth…

Asia-PacificJapanLucentisNovartisOphthalmicsPharmaceuticalRegulation

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

2014: A new dawn for pharma?

2014: A new dawn for pharma?

10-01-2014

We take a look at the week's top stories.

Asia-PacificManagementNovartisPharmaceuticalTeva Pharmaceutical IndustriesUK

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Japanese lawmakers are stepping in to Diovan investigation

07-10-2013

Members of Japan’s Diet (Congressmen) have formed a bipartisan study group to examine Swiss drug major…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalPoliticsRegulationResearch

Novartis under investigation for manipulating data in Japanese clinical trials

Novartis under investigation for manipulating data in Japanese clinical trials

27-09-2013

Swiss drug major Novartis has said it regrets the inconvenience caused by its investigator-initiated…

Asia-PacificCardio-vascularLegalNovartisPharmaceuticalRegulationvalsartan

Japan's MHLW approves 367 generics, but what does this mean?

21-08-2013

Japan's Ministry of Health Labor and Welfare (MHLW) approved 367 items of generic drugs last week. Launch…

Asia-PacificDiovanGenericsNovartisPharmaceuticalPricingRegulation

Novartis MenB vaccine approved in Australia

15-08-2013

Swiss drug major Novartis (NOVN: VX) revealed this morning (August 15) that the Australian Therapeutic…

Asia-PacificBexseroNovartisPharmaceuticalRegulationVaccines

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Novartis' research study questioned in Japan

15-07-2013

Swiss drug major Novartis (NOVN: VX) has admitted that there was an undisclosed conflict of interest…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalResearch

Proposal for a sole supply arrangement for fentanyl patches in New Zealand

08-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list a…

Asia-PacificfentanylFentanyl SandozNeurologicalNovartisPharmaceuticalPricingRegulationSandoz

CML drug revenue in Japan to grow, despite global decline, says GlobalData

21-05-2013

Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

India's NPPA says drugmakers cannot raise prices of imported products

10-05-2013

At a meeting earlier this month, India's drug price regulator the National Pharmaceutical Pricing Authority…

AllerganAsia-PacificNovartisPharmaceuticalPricingSanofi

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

US-India Business Council has concerns over India's ruling on Novartis' Glivec

03-04-2013

This week's long awaited Supreme Court of India ruling, which denied a patent on Swiss drug major Novartis'…

Asia-PacificGenericsGlivecNovartisPatentsPharmaceutical

India's Supreme Court denies Novartis Glivec patent appeal

02-04-2013

In a landmark decision issued on Monday (April 1) by the Indian Supreme Court has denied Swiss drug major…

Asia-PacificGenericsGlivecLegalNovartisOncologyPatentsPharmaceutical

Novartis Indian patent hearings close, but no verdict yet

05-12-2012

After more than 12 weeks of hearings in India's Supreme Court, humanitarian aid agency Medecins Sans…

Asia-PacificGlivecLegalNovartisPatentsPharmaceutical

MSF update on Novartis versus India, Supreme Court case

18-11-2012

Humanitarian health organization Medecins Sans Frontieres (MSF) says it continues to follow progress…

Asia-PacificGenericsGlivecLegalNovartisOncologyPatentsPharmaceutical

New Zealand decision on proposal for various Novartis products

05-11-2012

Following a public consultation, New Zealand's Pharmaceutical Management Agency PHARMAC yesterday announced…

Asia-PacificNovartisPharmaceuticalPricingRegulation

Access to many more medicines in Australia, as PBS list extended

28-10-2012

More than 110,000 Australians will benefit from better access to affordable medicines following the Australian…

Asia-PacificBayerEyleaMyforticNovartisPharmaceuticalPricingRegulation

1 to 25 of 32 results

Back to top